iRadimedvsJohnson & Johnson

IRMD and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

IRMD

iRadimed Corporation

$82.55

Value $1.1B

-1.08%
IRMD's page

iRadimed (IRMD) has a market value of $1.1B and Johnson & Johnson (JNJ) $667B. Over the last year, with dividends, IRMD moved -2.0% and JNJ +41.8%. The P/E is 44.0 for IRMD and 41.4 for JNJ. Dividend yield: IRMD 0.97%, JNJ 1.91%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    IRMD$1.1B

    JNJ$667B

    JNJ is 632 times IRMD

  • Revenue, 12 months

    IRMD$89M

    JNJ$99.3B

    JNJ is 1,112 times IRMD

  • Net income, 12 months

    IRMD$24M

    JNJ$16.1B

    JNJ is 671 times IRMD

  • Operating margin

    IRMD32.3%

    JNJ–

  • ROIC

    IRMD22.3%

    JNJ12.4%

    9.9 points apart

  • P/E

    IRMD44.0

    JNJ41.4

    IRMD is 1.1 times JNJ

  • Dividend yield

    IRMD1.0%

    JNJ1.9%

    0.9 points apart

  • 5-year return

    IRMD+132.1%

    JNJ+94.9%

    37.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

IRMD+132.1%

JNJ+94.9%

10020030020222023202420252026
Returns by period
PeriodIRMDWith dividendsJNJWith dividends
1 year since November 17, 2025-2.0%Price -3.4%+41.8%Price +38.7%
3 years since November 17, 2023+105.2%+27.1% a yearPrice +95.5%+101.2%+26.2% a yearPrice +84.8%
5 years since November 17, 2021+132.1%+18.3% a yearPrice +110.6%+94.9%+14.3% a yearPrice +69.5%
10 years since November 18, 2016+742.3%+23.8% a yearPrice +664.4%+212.6%+12.1% a yearPrice +139.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

IRMDiRadimedJNJJohnson & Johnson

Valuation

IRMDJNJ
Valuation
Price$82.55$276.76
Market value$1.1B$667B
Enterprise value (EV)$992M$694B
P/E44.041.4
P/E, 5-year median36.721.9
P/B9.98.2
EV/EBIT34.439.2
Free cash flow yield2.5%3.1%

Results and growth

IRMDJNJ
Results and growth
Revenue, 12 months$89M$99.3B
Net income, 12 months$24M$16.1B
Free cash flow, 12 months$26M$20.6B
Earnings per share, 12 months$1.87$6.59
Revenue growth, year on year14.4%6.1%
Revenue growth a year, past+21.5%over 5 years+2.7%over 5 years
EPS growth a year, past+73.9%over 5 years+14.9%over 5 years

Margins and returns on capital

IRMDJNJ
Margins and returns on capital
Gross margin75.5%67.6%
Operating margin32.3%–
Net margin26.9%16.2%
ROIC22.3%12.4%
ROE24.0%19.7%

Balance sheet

IRMDJNJ
Balance sheet
Cash$63M$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

IRMDJNJ
Dividends and buybacks
Dividend yield1.0%1.9%
Dividend per share, 12 months$0.80$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield1.0%2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: IRMD or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, iRadimed or Johnson & Johnson?

By market value, Johnson & Johnson ($667B) is about 632.1 times iRadimed ($1.1B), at today's prices.

How did IRMD and JNJ stock do over the last 10 years?

Since November 18, 2016, IRMD's price moved +664.4% and JNJ's +139.9%. With dividends: IRMD +742.3% (+23.8% a year), JNJ +212.6% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, IRMD or JNJ?

The dividend yield at today's price is 0.97% for iRadimed and 1.91% for Johnson & Johnson. Over the last twelve months they paid $0.80 and $5.28 per share.

What is the P/E of IRMD and JNJ?

At today's price, the P/E is 44.0 for IRMD and 41.4 for JNJ. The median of the last five years was 36.7 and 21.9, which shows where each stands against its own past.

Which has the higher profit margins, iRadimed or Johnson & Johnson?

Over the last twelve months, the net margin was 26.9% for iRadimed and 16.2% for Johnson & Johnson, and the operating margin 32.3% and –. Revenue was $89M and $99.3B.

Which is the better investment, iRadimed or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.